Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia.

Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost (2015) 2.46

Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis. Sci Rep (2016) 0.75

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet (2010) 4.20

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med (2007) 4.07

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med (2012) 3.20

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 2.62

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood (2012) 1.88

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood (2013) 1.84

A comment on Boyers et al.: "eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal". Pharmacoeconomics (2013) 1.09

A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Hum Mol Genet (2013) 1.05

Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin (2011) 0.83

Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. Qual Life Res (2011) 0.79

Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol (2012) 0.78

A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS. Clin Ther (2012) 0.76

Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med (2014) 0.76

Thrombophilia in patients with chronic immune thrombocytopenia. Scand J Clin Lab Invest (2014) 0.76

Validation of a guideline-based composite outcome assessment tool for asthma control. Respir Res (2007) 0.75

Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment. Transfus Med Hemother (2013) 0.75